A detailed history of Two Sigma Investments, LP transactions in Ovid Therapeutics Inc. stock. As of the latest transaction made, Two Sigma Investments, LP holds 40,669 shares of OVID stock, worth $30,501. This represents 0.0% of its overall portfolio holdings.

Number of Shares
40,669
Holding current value
$30,501
% of portfolio
0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

BUY
$2.72 - $4.04 $110,619 - $164,302
40,669 New
40,669 $124,000
Q3 2021

Nov 15, 2021

SELL
$3.31 - $4.04 $955,861 - $1.17 Million
-288,780 Closed
0 $0
Q2 2021

Aug 16, 2021

BUY
$3.3 - $4.49 $952,974 - $1.3 Million
288,780 New
288,780 $1.13 Million
Q1 2021

May 17, 2021

SELL
$2.42 - $4.47 $836,608 - $1.55 Million
-345,706 Closed
0 $0
Q4 2020

Feb 16, 2021

BUY
$2.28 - $6.84 $58,005 - $174,016
25,441 Added 7.94%
345,706 $799,000
Q3 2020

Nov 16, 2020

BUY
$5.39 - $8.24 $1.73 Million - $2.64 Million
320,265 New
320,265 $1.84 Million
Q2 2020

Aug 14, 2020

SELL
$2.67 - $7.91 $82,802 - $245,304
-31,012 Closed
0 $0
Q1 2020

May 15, 2020

SELL
$2.03 - $4.35 $279,307 - $598,516
-137,590 Reduced 81.61%
31,012 $92,000
Q4 2019

Feb 14, 2020

BUY
$2.08 - $5.06 $350,692 - $853,126
168,602 New
168,602 $700,000
Q3 2019

Nov 14, 2019

SELL
$1.76 - $3.51 $18,219 - $36,335
-10,352 Closed
0 $0
Q2 2019

Aug 14, 2019

SELL
$1.59 - $2.14 $50,892 - $68,497
-32,008 Reduced 75.56%
10,352 $19,000
Q1 2019

May 15, 2019

SELL
$1.77 - $3.56 $8,678 - $17,454
-4,903 Reduced 10.37%
42,360 $75,000
Q4 2018

Feb 14, 2019

BUY
$2.42 - $6.6 $114,376 - $311,935
47,263 New
47,263 $114,000

Others Institutions Holding OVID

About Ovid Therapeutics Inc.


  • Ticker OVID
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 70,419,400
  • Market Cap $52.8M
  • Description
  • Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company is developing OV101, a drug candidate, which is in Phase 2A clinical trials for the treatment of fragile X syndrome; OV329, a GABA aminotransferase inhibitor for the treatment o...
More about OVID
Track This Portfolio

Track Two Sigma Investments, LP Portfolio

Follow Two Sigma Investments, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Investments, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Investments, LP with notifications on news.